patients
DNDi_AR_2015
DNDi_AR_2015
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
STRENGTHENING EXISTING CAPACITIES<br />
Stabilization of investment in regional disease-specific networks to build capacity,<br />
conduct clinical research in endemic countries, facilitate treatment access,<br />
and disseminate information<br />
THREE REGIONAL CLINICAL RESEARCH PLATFORMS IN ENDEMIC COUNTRIES<br />
LEISHMANIASIS EAST AFRICA<br />
PLATFORM (LEAP)<br />
HUMAN AFRICAN TRYPANOSOMIASIS<br />
(HAT) PLATFORM<br />
LEAP + HAT PLATFORMS<br />
CHAGAS CLINICAL<br />
RESEARCH PLATFORM (CCRP)<br />
2015 KEY FINANCIAL PERFORMANCE INDICATORS<br />
EXPENDITURE FOR EACH PLATFORM<br />
IN 2015 vs 2014<br />
CHAGAS CLINICAL<br />
RESEARCH PLATFORM (CCRP)<br />
HUMAN AFRICAN<br />
TRYPANOSOMIASIS – HAT PLATFORM<br />
LEISHMANIASIS EAST AFRICA<br />
PLATFORM (LEAP)<br />
2014<br />
EUR 186 K<br />
2015<br />
EUR 225 K<br />
2014<br />
EUR 356 K<br />
2015<br />
EUR 263 K<br />
2014<br />
EUR 737 K<br />
2015<br />
EUR 628 K<br />
3 CLINICAL SITES<br />
10 CLINICAL SITES 7 CLINICAL SITES<br />
in Bolivia and Argentina in DRC and CAR in Ethiopia, Kenya, Sudan,<br />
and Uganda<br />
The overall platform budgets decreased by 13% between 2014 and<br />
2015 (from EUR 1’279 K in 2014 to EUR 1,115 K in 2015).<br />
• The Chagas platform expenditure (CCRP) increased by 21% because<br />
2015 was a year of transition characterized by a consolidation of<br />
the main clinical research groups, with a specific agenda for each<br />
one. Consequently, the number of trainings between 2014 and<br />
2015 increased by 129%. In addition the number of members of the<br />
platform grew by 23% (~40% of new members come from nonendemic<br />
countries) and this has a direct impact on the cost of the<br />
annual platform meeting.<br />
• The HAT platform expenditure decreased by 26% while the<br />
recruitment of the new coordinator was ongoing. Since mid-2015,<br />
with the arrival of the new coordinator of the HAT platform, the<br />
activities have fully resumed.<br />
• The Leishmaniasis East Africa platform (LEAP) costs decreased<br />
by 15%, due to the fact that the LEAP meeting was not organized<br />
together with a scientific day meeting as in 2014. LEAP continues<br />
to maintain clinical trial sites (mainly the team) even though they<br />
were not involved in R&D activities in 2015. The costs of these sites<br />
(Kimalel clinical trial site of KEMRI in Kenya, Abdu Rafi in Ethiopia,<br />
Kassab and Dooka in Sudan) were removed from R&D expenditures<br />
and allocated toward the strengthening capacities budget. Patients<br />
treated outside clinical trials in 2015 in the seven VL clinical trial sites<br />
reached 1,363 (3,910 people screened).<br />
People trained between 2014 and 2015<br />
increased by almost 50%<br />
DEVELOPING RESEARCH CAPACITIES IN ENDEMIC REGIONS<br />
In six years, platforms have been able to multiply by 7<br />
the number of people trained every year.<br />
154<br />
59<br />
95<br />
2010<br />
LEAP<br />
HAT platform<br />
CCRP<br />
240<br />
108<br />
62<br />
70<br />
2011<br />
316<br />
100<br />
131<br />
85<br />
2012<br />
X 7<br />
372<br />
132<br />
106<br />
134<br />
2013<br />
736<br />
275<br />
235<br />
226<br />
2014<br />
1,098<br />
482<br />
99<br />
517<br />
2015<br />
DNDi Annual Report 2015 › 61
Change language